Oligometastatic pancreatic cancer: current state of management and emerging therapies.

IF 4.8 2区医学 Q1 ONCOLOGY

Oncologist Pub Date : 2025-06-04 DOI:10.1093/oncolo/oyaf154

Andrii Khomiak, Nicole B Balmaceda, Sumaya A Ghaffar, Christopher H Lieu, Marco Del Chiaro, Wells A Messersmith, Robert W Lentz

引用次数: 0

Abstract

Oligometastatic pancreatic cancer is a distinct clinical entity with limited metastatic burden. This unique subset of patients harbor a favorable tumor biology and potentially better prognosis compared to widespread metastatic disease. This review explores definitions of oligometastatic pancreatic cancer and the current state of management, including systemic therapy, surgery, and locoregional techniques. While there are few randomized clinical trials directing the management of oligometastatic pancreatic cancer, we provide insights into the treatment challenges, evolving therapeutic approaches, and future directions for this unique subset of patients.

查看原文本刊更多论文

少转移性胰腺癌：管理现状和新兴疗法。

少转移性胰腺癌是一个独特的临床实体，转移负担有限。与广泛的转移性疾病相比，这种独特的患者亚群具有良好的肿瘤生物学和潜在的更好预后。这篇综述探讨了少转移性胰腺癌的定义和目前的管理状况，包括全身治疗、手术和局部技术。虽然很少有随机临床试验指导寡转移性胰腺癌的管理，但我们为这一独特患者群体提供了治疗挑战、不断发展的治疗方法和未来方向的见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oncologist 医学-肿瘤学

CiteScore

10.40

自引率

3.40%

发文量

309

审稿时长

3-8 weeks

期刊介绍： The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.